Analysts' Actions: CREE DIS MDRX TWX WLP


Cigna ( CI) was downgraded at Jefferies to hold from buy. Valuation call, as the stock is up 70% since July, Jefferies said. $75 price target.

Cree ( CREE) was downgraded at Sterne Agee to neutral. $59 price target. Estimates also cut, following negative checks in the lighting business, Sterne Agee said.

Disney ( DIS) was initiated with an outperform rating at BMO Capital. $76 price target. Company deserves a premium valuation, BMO Capital said.

Fusion-io ( FIO) was upgraded at UBS to buy from neutral. The stock price decline and strong flash demand overcompensate for the near-term risks, UBS said. Price target goes to $19.

Blackhawk ( HAWK) was initiated with a buy rating at Goldman Sachs. $28 price target. Company should see improved store productivity and growth through new products, Goldman said.

Allscripts Healthcare Solutions ( MDRX) was upgraded at Citigroup to buy from neutral. Next-generation solutions will capitalize on the population health opportunity, said Citigroup. Price target goes to $18.

Monster Beverage ( MNST) was initiated with an overweight rating at Morgan Stanley. $65 price target. Valuation does not fully reflect strong growth potential, Morgan Stanley said.

Melco Crown ( MPEL) was downgraded at UBS to neutral from buy. Operations and liquidity have improved recently, with these events now priced in, UBS said. Price target goes to $26.

Solarcity ( SCTY) was downgraded at Credit Suisse to neutral from outperform. Valuation call, based on a $28 price target, Credit Suisse said.

Time Warner ( TWX) was initiated with a market-perform rating at BMO Capital. Valuation call, based on a $64 price target, BMO Capital said.

Vivus was downgraded at Lazard Capital Markets to neutral from buy. The window of opportunity is closing for Qsymia in the obesity market, Lazard Capital Markets said.

Wellpoint ( WLP) was upgraded at Jefferies to buy from hold. $92 price target. Buybacks will help boost growth, Jefferies said.


Mosaic ( MOS) price target and estimates were updated at UBS. Estimates were adjusted after announcing plans to repurchase shares and raise its dividend, UBS said. Price target was raised to $68.

If you liked this article you might like

Market Rally Fades as Dow, S&P 500 and Nasdaq Finish Lower

Wall Street Holds Lower as Consumer, Defense Names Decline

Cree Lights Up for a Breakout

Analysts' Actions -- Arconic, Big Lots, Chipotle, Snap and More